BoostmybodyYou decide

For a closer look

Research Library

Read what researchers wanted to find out and what it means in everyday words. Open the details if you want to see how a study was done. The product pages have a shorter explanation.

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Showing research linked to CJC-1295 No DAC.

Back to the short explanation

2 studies found

Research context

The human trial was DAC, not No-DAC

Healthy adults in two short trials of long-acting CJC-1295

What did they want to find out?

Did the long-acting compound raise GH and IGF-I?

What did researchers observe?

It raised both measured hormones and persisted for days.

What does this mean for you?

This is evidence about the DAC-development compound's hormone effects, not this catalog's No-DAC preparation.

What we still do not know

No-DAC fitness benefits or a days-long half-life cannot be inferred from this trial.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Journal of Clinical Endocrinology and Metabolism · 2006

How it was studied

Two randomized double-blind placebo-controlled trials of long-acting CJC-1295 with DAC. Healthy adults aged 21–61; trial durations 28 and 49 days; total count not supplied in the accessed abstract.

Study finding

The long-acting compound raised GH and IGF-I; reported half-life was 5.8–8.1 days.

Study limitations

Related DAC evidence, not direct No-DAC evidence. Hormone increases do not demonstrate improved fitness, sleep or injury recovery; short follow-up cannot establish long-term safety.

Who is behind the study?

Identified authors
Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman
Funding and involvement
Not confirmed from the accessed abstract and publisher author sections.
Disclosed interests and verification limits
Lawrence, Gagnon and Castaigne list ConjuChem; Teichman and Neale list WinPharm; Frohman lists University of Illinois. Commercial coauthorship is disclosed; formal individual interests and sponsor roles were not confirmed.

Terms explained

DAC
Drug Affinity Complex: a modification used in the long-acting development compound.
IGF-I
A growth-related blood marker; a rise is not proof of better fitness.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source
Research context

One name can hide different preparations

Chemical analysis of one seized preparation

What did they want to find out?

What structural features did the material have?

What did researchers observe?

It contained a 29-amino-acid peptide with a terminal amide.

What does this mean for you?

Naming something CJC-1295 is not enough to establish that it matches a clinical-trial compound.

What we still do not know

This was not a human trial and does not verify a current No-DAC vial.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation

Drug Testing and Analysis · 2010

How it was studied

Laboratory chemical identification using mass spectrometry. One unknown preparation submitted after seizure in 2009; no patient treatment.

Study finding

The preparation contained a 29-amino-acid peptide with a terminal amide, consistent with material marketed as CJC-1295.

Study limitations

This establishes an analyzed sample's structural features, not human benefit or the identity of today's No-DAC products. Complete sequence is not supplied in the accessed abstract.

Who is behind the study?

Identified authors
John Henninge, Milaim Pepaj, Ingunn Hullstein, Peter Hemmersbach
Funding and involvement
Not confirmed from the accessed source sections.
Disclosed interests and verification limits
Authors list the Norwegian Doping Control Laboratory, Oslo University Hospital. Police/customs requested analysis; that request is not an identified funding grant. Formal author interests were not confirmed.

Terms explained

Mass spectrometry
A laboratory method used to investigate what a molecule is.
Terminal amide
A chemical feature at one end of a peptide.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source